|
NON-SMALL CELL LUNG CANCER (NSCLC)
A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) (ECOG E1505):
- Patients must have undergone complete resection
of their cancer prior to enrollment
- Patients must be no less than 6 weeks and no
more than 12 weeks post-thoracotomy and must be adequately recovered
from surgery
- Patients must not have received the following: Prior systemic chemotherapy at any time, Hormonal cancer therapy or radiation therapy prior cancer treatment
|
